Clinical Significance
- Determines tumor responsiveness to targeted therapies like Cetuximab or Panitumumab.
- Prevents the use of ineffective treatments in patients with mutations.
- Optimizes the clinical outcome by personalizing the oncology care plan.
Book KRAS/NRAS Mutation Test | Lahalak Medical Platform
A vital molecular diagnostic test identifying KRAS and NRAS mutations to guide targeted therapy for metastatic colorectal cancer, ensuring patients receive the most effective biological treatment based on their genetic profile.
Scientific name: KRAS and NRAS Mutation Testing for Colorectal Cancer
An advanced molecular test on tissue biopsies detecting genetic mutations in KRAS and NRAS genes. It determines eligibility for anti-EGFR therapies, helping oncologists customize treatment plans for metastatic colorectal cancer patients.
Service type
Molecular Laboratory Test
Duration
15-20 minutes
Fasting
Fasting is not required
Included Services
- KRAS Mutation Analysis
- NRAS Mutation Analysis
- Detailed Clinical Report
Medical Service Information
Target Groups
- Patients diagnosed with metastatic colorectal cancer (mCRC).
- Patients being considered for anti-EGFR targeted therapy.
- Cases where initial chemotherapy has failed and new options are needed.
Interpretation of Results
- Wild-Type: Indicates the patient is likely to benefit from anti-EGFR therapy.
- Mutant: Indicates the therapy is unlikely to work, guiding the doctor to other options.
Conditions & Notices
- Formalin-fixed paraffin-embedded (FFPE) tissue block required
- Previous pathology report must be provided
Medical services you might also like
